Skip to main content
Erschienen in: Journal of Radiation Oncology 3/2019

12.08.2019 | Original Research

Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma

verfasst von: Anesa Ahamad, Sharon Salenius, Rudi Ross, Raj Selvaraj, Eduardo Fernandez

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To study radiotherapeutic treatment approaches in larynx-preservation for T2N0M0 glottic carcinoma at free-standing centers in the USA.

Methods

We retrospectively audited fractionation and chemoradiation at 59 centers in 5 geographic regions from 2000 to 2015. Chi-squared test and Fisher’s exact test were used to compare frequencies, the Cox proportional hazards model and Kaplan-Meier procedure were used for survival analyses, and log-rank test to compare survival curves.

Results

Among 180 patients, chemoradiation, accelerated hypofractionation (2.25 Gy/fraction), and hyperfractionation was given to 14.4%, 13.3%, and 13.3%, respectively. Hypofractionation rates varied by geographic location: western/southern 33%, northeast 18.6%, Florida 5.6%, and Michigan 0% (p < 0.001). Conversely, hyperfractionation rates were as follows: Florida 23.6%, Michigan 14%, southern 9.5%, northeast and western 0% (p < 0.001). Hypofractionation increased from 6.3% in 2000–2004 to 25.0% in 2010–2015 (p < 0.001) and steadily declined for hyperfractionation. Chemoradiation did not vary by region but increased over time: 0% in 2000–2004, 17.6% in 2010–2015(p = 0.029).
At mean follow-up at 32.3 months, 36 months survivals were as follows: accelerated fractionation 85%, hyperfractionation 81%, and standard fractionation 66%, (p = 0.01); treatment duration < 50 days 82%, > 50 days 59% (p = 0.03). There was no difference in overall survival, progression-free survival, or locoregional-recurrence-free survival between chemoradiation and radiotherapy-only (all fractionations). Accelerated fractionation, (the fractionation with the highest survival) gave similar 36 months survivals as chemoradiation: 85% and 68%, respectively (p = 0.69). Chemoradiation worsened acute grades 2–4 toxicity rate versus radiotherapy-only: 80.8% and 54.5%, respectively (p = 0.01, univariate and multivariate).

Conclusions

Hypofractionation gave superior survival than standard fractionation for glottic T2N0M0 tumors. Its use varies among treatment centers but is increasing with time. Chemoradiation gave a lower therapeutic ratio: more than 30% greater acute toxicity without improvement of survival; yet, its use is growing over time. More explicit guidelines are needed.
Literatur
1.
Zurück zum Zitat Forastiere AA, Ismaila N, Lewin JS et al Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. https://doi.org/10.1200/JCO.2017.75.7385 - published online before print November 27, 2017 Forastiere AA, Ismaila N, Lewin JS et al Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. https://​doi.​org/​10.​1200/​JCO.​2017.​75.​7385 - published online before print November 27, 2017
2.
Zurück zum Zitat Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW (2001) T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19:4029–4036CrossRef Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW (2001) T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19:4029–4036CrossRef
3.
Zurück zum Zitat Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ (1998) T1-T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41:347–353CrossRef Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ (1998) T1-T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41:347–353CrossRef
8.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC Cancer staging manual, 7th edn. Springer, New York, pp 57–67 Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC Cancer staging manual, 7th edn. Springer, New York, pp 57–67
10.
Zurück zum Zitat Cox JD, Stetz JA, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346CrossRef Cox JD, Stetz JA, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346CrossRef
12.
Zurück zum Zitat Barendsen GW (1982) Dose fractionation. Dose-rate and iso-effect relationships for normal tissue responses. Intl J Radiat Oncol Biol Phvs 8:1991–1997 Barendsen GW (1982) Dose fractionation. Dose-rate and iso-effect relationships for normal tissue responses. Intl J Radiat Oncol Biol Phvs 8:1991–1997
13.
Zurück zum Zitat Fowler IF (1989) The linear-quadratic formula and progress in fractionation. Br J Radiol 62:679–694CrossRef Fowler IF (1989) The linear-quadratic formula and progress in fractionation. Br J Radiol 62:679–694CrossRef
14.
Zurück zum Zitat Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK (2003) Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 55:322–328CrossRef Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK (2003) Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 55:322–328CrossRef
15.
Zurück zum Zitat Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM (2010) T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 78:461–466CrossRef Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM (2010) T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 78:461–466CrossRef
16.
Zurück zum Zitat Le QT, Fu KK, Kroll S et al (1997) Influence of fraction size, total dose, and overall time on local control of t1-t2 glottic carcinoma. Int J Radiat Oncol Biol Phys 39:115–126CrossRef Le QT, Fu KK, Kroll S et al (1997) Influence of fraction size, total dose, and overall time on local control of t1-t2 glottic carcinoma. Int J Radiat Oncol Biol Phys 39:115–126CrossRef
17.
Zurück zum Zitat Yu E, Shenouda G, Beaudet MP, Black MJ (1997) Impact of radiation therapy fraction size on local control of early glottic carcinoma. Int J Radiat Oncol Biol Phys 37(3):587–591CrossRef Yu E, Shenouda G, Beaudet MP, Black MJ (1997) Impact of radiation therapy fraction size on local control of early glottic carcinoma. Int J Radiat Oncol Biol Phys 37(3):587–591CrossRef
18.
Zurück zum Zitat Kim TG, Ahn YC, Nam HR, Chung MK, Jeong HS, Son YI, Baek CH (2012) Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules. Clin Exp Otorhinolaryngol 5(2):94–100CrossRef Kim TG, Ahn YC, Nam HR, Chung MK, Jeong HS, Son YI, Baek CH (2012) Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules. Clin Exp Otorhinolaryngol 5(2):94–100CrossRef
19.
Zurück zum Zitat Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64:77–82CrossRef Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64:77–82CrossRef
20.
Zurück zum Zitat Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, Kang KM, Lee JY, Chung WK, Park WY, Kim JH (2014) A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 110(1):98–103. https://doi.org/10.1016/j.radonc.2013.09.016 CrossRefPubMed Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, Kang KM, Lee JY, Chung WK, Park WY, Kim JH (2014) A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 110(1):98–103. https://​doi.​org/​10.​1016/​j.​radonc.​2013.​09.​016 CrossRefPubMed
21.
Zurück zum Zitat Scott MT, Dosch A, Elsayyad N et al (2015) Therapeutic ratio of hypofractionation in early glottic cancer: a topic worth revisiting? Contemp Radiat Oncol 1:13–19 Scott MT, Dosch A, Elsayyad N et al (2015) Therapeutic ratio of hypofractionation in early glottic cancer: a topic worth revisiting? Contemp Radiat Oncol 1:13–19
23.
Zurück zum Zitat Horiot JC, Le Fur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241CrossRef Horiot JC, Le Fur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241CrossRef
24.
Zurück zum Zitat Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK (2014) Final results of local-regional control and late toxicity of RTOG 90-03: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89:13–20CrossRef Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK (2014) Final results of local-regional control and late toxicity of RTOG 90-03: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89:13–20CrossRef
26.
Zurück zum Zitat Kimura K, Itoh Y, Okada T et al (2015) Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. Anticancer Res 35(4):2385–2390PubMed Kimura K, Itoh Y, Okada T et al (2015) Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. Anticancer Res 35(4):2385–2390PubMed
28.
Zurück zum Zitat Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H (2006) Concurrent chemoradiotherapy with carboplatin and uracil-tegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol 120(6):478–481CrossRef Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H (2006) Concurrent chemoradiotherapy with carboplatin and uracil-tegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol 120(6):478–481CrossRef
29.
38.
Zurück zum Zitat Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA (2017) Hypofractionated radiotherapy for patients with early stage glottic cancer: patterns of care and survival. Natl Cancer Inst 109(10). https://doi.org/10.1093/jnci/djx042 Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA (2017) Hypofractionated radiotherapy for patients with early stage glottic cancer: patterns of care and survival. Natl Cancer Inst 109(10). https://​doi.​org/​10.​1093/​jnci/​djx042
Metadaten
Titel
Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma
verfasst von
Anesa Ahamad
Sharon Salenius
Rudi Ross
Raj Selvaraj
Eduardo Fernandez
Publikationsdatum
12.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2019
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00397-9

Weitere Artikel der Ausgabe 3/2019

Journal of Radiation Oncology 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.